Who is sponsoring NCT02187562?

NCT02187562 is sponsored by Boehringer Ingelheim.

What drugs are being tested in NCT02187562?

Interventions: Meloxicam, Aspirin.

What is the status of NCT02187562?

NCT02187562 is currently COMPLETED.

Last reviewed 2014-07-11 · How we verify

Effect of Steady State Meloxicam 15 mg/Day on Low Dose Aspirin (100 mg/Day) Induced Inhibition of Platelet Aggregation and Thromboxane Synthesis in Healthy Males and Females. An Open, Randomised, Two-way Crossover Study.

NCT02187562 Phase 1 COMPLETED

The objective of this study was to investigate the influence of meloxicam on low dose aspirin induced inhibition of platelet aggregation and thromboxane B2, when meloxicam is given before aspirin.

Details

Lead sponsor	Boehringer Ingelheim
Phase	Phase 1
Status	COMPLETED
Enrolment	16
Start date	2002-07

Conditions

Healthy

Interventions

Meloxicam
Aspirin

Primary outcomes

Arachidonic acid induced platelet aggregation — up to day 11 (treatment 1), up to day 3 (treatment 2)